The AVAREF joint review process of Ebola clinical trial applications
|
|
- Antony Richards
- 8 years ago
- Views:
Transcription
1 The AVAREF joint review process of Ebola clinical trial applications Dr Matthias Stahl, Regulation, Ebola R&D Team 1
2 Background WHO convened the 9 th annual meeting of the African Vaccine Regulatory Forum (AVAREF) on 3 7 November The first two days of the meeting were devoted to Ebola, in light of the global response to the current outbreak in West Africa and the need to accelerate the development and use of products against the disease. 2
3 Background The ethics committees and regulatory authorities of the 23 African countries present at the meeting agreed to the following: That WHO would convene and facilitate a joint review of the GSK ChAd3 Ebola Vaccine Clinical Trials (CT) phase II submission on 15 December That the CT submission to the target countries would follow the AVAREF common CT application format, to allow for a joint review. That each regulatory agency would designate reviewers with the mandate to take regulatory/ethics decisions. That NRAs and ECs of the 3 Ebola-affected countries would participate as observers (capacity building) That WHO would seek the assistance of the US FDA, EMA, Health Canada, and Swissmedic to provide technical support at the meeting. 3
4 On 12 Nov 2014 WHO convened a TC with the heads of the regulatory authorities and ECs of the target countries (Cameroon, Ghana, Mali, Nigeria and Senegal), as well as Guinea, Liberia, and Sierra Leone, to agree on the joint review process and secure nomination of representatives. WHO facilitated the development and submission of CT applications by GSK and its partner, Quintiles, ahead of the joint review meeting. GSK submission to the ECs and the regulatory authorities included (by 9 Dec); 4
5 1. Letter from Quintiles and GSK addressed to Regulatory Authorities/IRBs/IECs and Investigators. 2. Adult Protocol for the Phase II study. 3. Investigator Brochure (IB) for the investigational vaccine: Recombinant chimpanzee adenovirus type3-vectored Ebola Zaire vaccine (ChAd3-EBO- Z). 4. CMC Annex. The CMC Annex provides information on the chemistry, manufacturing and controls of the investigational vaccine. 5. Adult ICF (Informed Consent Form) 6. Paediatric Protocol and the relevant ICFs/Assents. 5
6 WHO also set up a SharePoint site for queries from the regulators, as well as the SRAs involved, for GSK to access to be able to prepare their responses ahead of the Dec joint review in Geneva. WHO facilitated a waiver of confidentiality from GSK to enable US FDA and EMA to share - with the meeting participants - the outcomes of their previous review and assessment of this product. 6
7 At the 15&16 Dec joint review meeting; GSK protocol presented, followed by Q&A. Queries on SharePoint addressed by GSK, Quintiles, and investigators from the field sites of the clinical trials. The characteristics of the field sites, including target populations and clinical and laboratory capacities were presented. USFDA, EMA, HC and Swissmedic summarized the outcome of their previous assessments Questions were raised by the reviewers and responses provided. In the end a closed session of regulators where further issues were raised and posted on the SharePoint site to be addressed by GSK and partners. 7
8 The parties signed on to the following: GSK; 1. First wave submission (add data) by 12 January 2015 a. To include protocols, ICF/assent for adolescents, complete CMC module, IB for candidate and control vaccines, CVs of investigators, GCP certificates, b. Draft DSMB (data safety monitoring board; unsigned), membership, and CVs of members c. French translation of protocol and ICF d. French and English version of diary card and ID cards e. Draft budget and contract 8
9 2. Second wave during the 4 th week of January. a. Pharmacy manual (including selected dose); and rationale for the dose. b. Country specific addendum c. Insurance cover d. Signed contract and budget e. Final DSMB (signed) f. GMP certificates and certificates of analysis g. If additional data is needed to determine the dose, GSK will communicate to all stakeholders. 3. Submissions will be by paper copy and by signed electronic copy in a pdf format on CD or DVD 4. GSK to list, whatever has been included, in the cover letter that accompanies the first wave of submission 9
10 All the countries confirmed that they will respond to the sponsor within two weeks (10 working days) from receipt of submission, and approval will be communicated as follows: 1. Ghana (simultaneous review by EC and NRA) Response in 2 weeks 2. Nigeria (simultaneous review by EC and NRA) Response in 2 weeks 3. Mali (sequential review by EC followed by NRA) Response in 2 weeks 4. Cameroon (sequential review by EC followed by NRA) Response in 2 weeks 10
11 Joint review of phase I CT applications WHO was approached by J&J to facilitate joint review and approval of their phase I trials (Kenya, Tanzania and Uganda, as well as Ghana). Joint review - facilitated by WHO - planned for 21 & 22 Jan (Tanzania; EMA, HC, USFDA, MHRA present). Rwanda, Burundi and Zanzibar potential observers. Planned approval of applications at the meeting. J&J has just confirmed submission to countries. 11
12 Joint review of phase III CT applications On 17 Dec WHO facilitated meeting in Geneva for sponsors and investigators to brief regulators and ECs of Guinea, Liberia and Sierra Leone on planned Phase III Clinical Trials of Vaccines against Ebola. Participants: Members of ECs and NRAs of Liberia, Guinea and Sierra Leone, vaccine manufacturers, investigators and sponsors from WHO, CDC, NIH, Merck/Newlink, GSK and J&J. Updates by J&J, GSK and Merck/Newlink, on Ebola vaccine characteristics and preliminary safety and immunogenicity data (Phase I trials data and NHP data). 12
13 Joint review phase III CT applications Three proposals for phase III clinical trials in affected countries were presented. Q&A on the ethics and regulatory and safety aspects of the proposed studies. Specific issues included the following: How to set up Pharmacovigilance system to monitor the studies Information and knowledge sharing system between the 3 countries Joint on site-gcp inspections through the African Medicines Regulatory Harmonization (AMRH) initiative. 13
14 Joint review of phase III CT applications Closed session with the WHO secretariat to identify country needs; a work plan was developed to address those needs (GCP training, joint GCP inspections, safety monitoring etc). A joint review is planned for early February (Ghana; dates TBD) of phase III trials (CDC - SL, NIH - Liberia, WHO consortium - Guinea) by the 3 high-impact countries. 14
The Rapidly Evolving Regulatory Landscape in Africa
The Rapidly Evolving Regulatory Landscape in Africa B. Dicky Akanmori Regional Advisor, Vaccine Regulation Immunization, Vaccines & Emergencies Cluster What has changed? Prime targets for vaccine development
More informationFAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE
FAST TRACK DEVELOPMENT OF EBOLA VACCINES: FDA REGULATORY PERSPECTIVE Marion Gruber, Ph.D. Director Office of Vaccines Research & Review Center for Biologics Evaluation and Research US Food and Drug Administration
More informationNRA FUNCTION IN CONTROLLING VACCINES IN CLINICAL TRIAL AND MARKETING AUTHORIZATION INDONESIA 2013 DVI MEETING 9 11 APRIL 2013 1
NRA FUNCTION IN CONTROLLING VACCINES IN CLINICAL TRIAL AND MARKETING AUTHORIZATION INDONESIA 2013 DVI MEETING 9 11 APRIL 2013 1 2 The National Agency of Drug and Food Control (NA-DFC) is a non departmental
More informationThe Effective Vaccine Management Initiative Past, Present and Future
EVM setting a standard for the vaccine supply chain The Effective Vaccine Management Initiative Past, Present and Future Paul Colrain TechNet meeting Dakar, Senegal, February 2013 February 2013 TechNet
More informationThe Clinical Trials Regulation EU No 536/2014: and Phase I trials
The Clinical Trials Regulation EU No 536/2014: and Phase I trials EUFEMED, Brussels, 20 May 2015 Presented by Fergus Sweeney Head, Inspections and Human Medicines Pharmacovigilance An agency of the European
More informationPROJECT INFORMATION DOCUMENT (PID) ADDITIONAL FINANCING Report No.: PIDA26027. Project Name Parent Project Name. Region Country
PROJECT INFORMATION DOCUMENT (PID) ADDITIONAL FINANCING Report No.: PIDA26027 Project Name Parent Project Name Region Country Africa Medicine Regulatory Harmonization Project (P155163) AFCC2/RI-African
More informationTHE ROLE OF BIG DATA/ MOBILE PHONE DATA IN DESIGNING PRODUCTS TO PROMOTE FINANCIAL INCLUSION
THE ROLE OF BIG DATA/ MOBILE PHONE DATA IN DESIGNING PRODUCTS TO PROMOTE FINANCIAL INCLUSION Joseph Nketsiah GM, Risk Management Division, HFC BANK www.hfcbank.com.gh 1 Using customer data for marketing
More informationThe EU portal and database
The EU portal and database ECPC General Assembly - 20 June 2015 Presented by Laura Pioppo Clinical and Non-clinical Compliance Service An agency of the European Union Table of contents Legal basis CT programme
More information2.2 Roles and Responsibilities in the Conduct and Assessment of Clinical Trials
L1 2.2 Roles and Responsibilities in the Conduct and Assessment of Clinical Trials Presentation to APEC Preliminary Workshop on Review of Drug Development in Clinical Trials Celia Lourenco, PhD, Manager,
More informationDEFINITION OF THE CHILD: THE INTERNATIONAL/REGIONAL LEGAL FRAMEWORK. The African Charter on the Rights and Welfare of the Child, 1990
DEFINITION OF THE CHILD: THE INTERNATIONAL/REGIONAL LEGAL FRAMEWORK Article 2: Definition of a Child The African Charter on the Rights and Welfare of the Child, 1990 For tile purposes of this Charter.
More informationE4impact & Scalability
E4impact & Scalability Mario Molteni E4impact Director ALTIS Università Cattolica (Milano) 1) A case of scaling 2) A tool for scaling 1. A case of scaling 2 E4impact vision The leading Pan-African University
More informationUNFCCC initiatives: CDM and DNA Help Desks, the CDM Loan Scheme, Regional Collaboration Centres
UNFCCC initiatives: CDM and DNA Help Desks, the CDM Loan Scheme, Regional Collaboration Centres Africa Carbon Forum 03 July 2013 - Abidjan, Côte d Ivoire Ms. Flordeliza Andres Programme Officer, UNFCCC
More informationcountry profiles WHO regions
country profiles WHO regions AFR AMR EMR EUR SEAR WPR Algeria Total population: 37 63 aged years and older (+): 73% in urban areas: 66% Income group (World Bank): Upper middle income 196 196 197 197 198
More informationADF-13 Mid Term Review: Progress on the African Development Bank Group s Gender Agenda
ADF-13 Mid Term Review: Progress on the African Development Bank Group s Gender Agenda Investing in Gender Equality for Africa s Transformation The AfDB Group Ten-Year Strategy Twin Objectives: Inclusive
More informationManufacturing & Reproducing Magnetic & Optical Media Africa Report
Brochure More information from http://www.researchandmarkets.com/reports/3520587/ Manufacturing & Reproducing Magnetic & Optical Media Africa Report Description: MANUFACTURING & REPRODUCING MAGNETIC &
More informationMarieme Ba for CAAST-NET + 1 st stakeholder meeting Entebbe November 2014
Coming together is a beginning, keeping together is progress, working together is success. - Henry Ford - Considering the clinical research industry as an area for enhanced public-private sector collaboration
More informationPROCEEDINGS KIGALI 3-4 NOVEMBRE,
PROCEEDINGS KIGALI 3-4 NOVEMBRE, 2005 The 7 th Conference of Ministers Responsible for Animal Resources was held in the conference room of Intercontinental hotel - Kigali (Rwanda) from 3 rd to 4 th November
More informationClinical trials: from European perspective to National implementation. CTFG / FAMHP / pharma.be. Brussels, 19 November 2010
Clinical trials: from European perspective to National implementation CTFG / FAMHP / pharma.be Brussels, 19 November 2010 Safety in clinical trials: From detection to decision How safety events are captured
More informationEMA Update Clinical Trials
EMA Update Clinical Trials Fergus Sweeney, Head, Compliance and Inspections, European Medicines Agency 16 October 2012 An agency of the European Union Disclaimer The views presented in this presentation/these
More informationRoles & Responsibilities of the Sponsor
Roles & Responsibilities of the Sponsor Developed by Center for Cancer Research, National Cancer Institute, NIH Endorsed by the CTN SIG Leadership Group Objectives Funding for clinical research comes from
More informationTRIAL MASTER FILE- SPONSORED
gsop-06-04 - Management of TMF for ENHT/ WHHT Sponsored CTIMPs Page 1 of 16 Hertfordshire Hospitals R&D Consortium Incorporating West Herts Hospitals NHS Trust and East & North Herts NHS Trust TRIAL MASTER
More informationEU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE
EU DIRECTIVE ON GOOD CLINICAL PRACTICE IN CLINICAL TRIALS DH & MHRA BRIEFING NOTE Purpose 1. The Clinical Trials Directive 2001/20/EC heralds certain additional responsibilities for the Medicines and Healthcare
More informationThe Role of AFREXIMBANK in Promoting Factoring in Africa
The Role of AFREXIMBANK in Promoting Factoring in Africa By Mr. Teddy NGIDJOL Manager, Trade Finance and Branches (AFREXIMBANK) Presentation at Afreximbank s Seminar on Factoring Lusaka, Zambia November
More informationFinancing Agro-Business and Food Processing in Nigeria. Oti Ikomi Head, Corporate Banking Products Ecobank Group, South Africa March 8, 2011
Financing Agro-Business and Food Processing in Nigeria Oti Ikomi Head, Corporate Banking Products Ecobank Group, South Africa March 8, 2011 1 Outline Overview of Agribusiness Value Chain Challenges of
More information[NAME OF NATIONAL REGULATORY AUTHORITY] PROCEDURE FOR SUBMISSION CLINICAL TRIAL APPLICATIONS VACCINES AND BIOLOGICALS [COUNTRY]
[TEMPLATE] [NAME OF NATIONAL REGULATORY AUTHORITY] PROCEDURE FOR SUBMISSION OF CLINICAL TRIAL APPLICATIONS OF VACCINES AND BIOLOGICALS IN [COUNTRY] 1of 19 General Procedures for clinical trial applications
More informationWhat is necessary to provide good clinical data for a clinical trial?
What is necessary to provide good clinical data for a clinical trial? Alain Barrois, Assistant Clinical Trials Operations Manager #EBMT2015 www.ebmt.org Is this a (typical) clinical trial? 2 Agenda Introduction
More informationClinical Trials - Funding Africa's Best Practice
The European & Developing Countries Clinical Trials Partnership () 23.07.2015 Dr. Claudia Schacht & Julia Buech Eurice GmbH Content 1. overview: a) Background and Mission b) Scope 2. Project types and
More informationUNHCR, United Nations High Commissioner for Refugees
Belgium 22 Jul 1953 r 08 Apr 1969 a Belize 27 Jun 1990 a 27 Jun 1990 a Benin 04 Apr 1962 s 06 Jul 1970 a Bolivia 09 Feb 1982 a 09 Feb 1982 a Bosnia and Herzegovina 01 Sep 1993 s 01 Sep 1993 s Botswana
More informationICRIN Seminar on EU Regulation of Clinical Trials
ICRIN Seminar on EU Regulation of Clinical Trials 12 th March 2013, Dublin J. Michael Morris Director Scientific Affairs IRISH MEDICINES BOARD 28/03/2013 Slide 1 Overview Clinical Trial (CT) legislation
More informationAdopted by the Security Council at its 7268th meeting, on 18 September 2014
United Nations S/RES/2177 (2014) Security Council Distr.: General 18 September 2014 Resolution 2177 (2014) Adopted by the Security Council at its 7268th meeting, on 18 September 2014 The Security Council,
More informationInternet Society (ISOC)
Internet Society (ISOC) African Regional Bureau Dawit Bekele, Manager, African Regional Bureau INET Africa, Abuja, May 4 2007 1 Internet Society Who we are Founded 1991 by Internet Pioneers International,
More informationEuropean & Developing Countries Clinical Trials Partnership (EDCTP)
European & Developing Countries Clinical Trials Partnership (EDCTP) EDCTP funding opportunities Lara Pandya North-North Networking Officer EDCTP 13 June 2015 What is different in EDCTP2? New legal structure:
More informationStates Parties to the 1951 Convention relating to the Status of Refugees and the 1967 Protocol
States Parties to the 1951 Convention relating to the Status of Refugees and the 1967 Protocol Date of entry into force: 22 April 1954 (Convention) 4 October 1967 (Protocol) As of 1 October 2008 Total
More informationMigration and Development in Africa: Implications for Data Collection and Research
Migration and Development in Africa: Implications for Data Collection and Research Marzia Rango Migration Research Division IOM UN DESA workshop on strengthening the collection and use of migration data
More informationSUN Movement Meeting of the Network of SUN Countries: Report of the 17 th Meeting- 26 th January to 2 nd February 2015
SUN Movement Meeting of the Network of SUN Countries: Report of the 17 th Meeting- 26 th January to 2 nd February 2015 The 17 th meeting of the SUN Movement Network of SUN countries took place from January
More informationEmergency Use Assessment and Listing Procedure (EUAL) for candidate vaccines for use in the context of a public health emergency
Emergency Use Assessment and Listing Procedure (EUAL) for candidate vaccines for use in the context of a public health emergency Introduction The 2014 Ebola outbreak is the largest Ebola epidemic in history,
More informationDrug Regulations in India Dr. Surinder Singh Drugs Controller General (India) Meeting With Ambassadors / High Commissioners of African Countries 24
Drug Regulations in India Dr. Surinder Singh Drugs Controller General (India) Meeting With Ambassadors / High Commissioners of African Countries 24 th April 2009, New Delhi Flow of presentation About Indian
More informationThe Regulatory Binder/Trial Master File: Essential Records for the Conduct of a Clinical Trial
The Regulatory Binder/Trial Master File: Essential Records for the Conduct of a Clinical Trial Clinical Research Operations & Regulatory Support (CRORS) Ann Glasse, RN, BSN, MBA Director-CRORS Objectives
More informationSummary of GAVI Alliance Investments in Immunization Coverage Data Quality
Summary of GAVI Alliance Investments in Immunization Coverage Data Quality The GAVI Alliance strategy and business plan for 2013-2014 includes a range of activities related to the assessment and improvement
More informationClinical trials in developing countries submitted to EMEA for regulatory purposes
Clinical trials in developing countries submitted to EMEA for regulatory purposes Rome, UNICRI/AIFA December 2008 Hans-Georg Eichler Agenda Challenges EU regulatory requirements for clinical trials Facts
More informationFinancing Education for All in Sub Saharan Africa: Progress and Prospects
Financing Education for All in Sub Saharan Africa: Progress and Prospects Albert Motivans Education for All Working Group Paris, 3 February 211 1 Improving the coverage and quality of education finance
More informationmsos Mobile SMS-based disease outbreak alert system
National Council for Science and Technology KICC 16 May, 2013 Nairobi, Kenya msos Mobile SMS-based disease outbreak alert system Mitsuru Toda 1,2 Dr. Ian Njeru 3, Dr. Shikanga O-Tipo 3, Mr. David Kareko
More informationEMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART
EMA Clinical Laboratory Guidance - Key points and Clarifications PAUL STEWART Framework Labs generate data that are used to make decisions on the safety and efficacy of medicinal products; consequently,
More informationHealth Canada s GCP Compliance Program. GCP Information Sessions November 2010
Your Health and Safety... Our priority Votre santé et votre Securité notre priorité Health Canada s GCP Compliance Program GCP Information Sessions November 2010 Objective To describe the role that Health
More informationEthics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong. Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015
Ethics and Scientific Oversight for Phase 1 Clinical Trials in Hong Kong Sydney TANG Chairman, HKU/HA HKW IRB November 21, 2015 Clinical Trials at HKU Phase 1 Phase II Phase III Phase IV Conducted on patient
More informationBetter Data, Stronger Health Workforce The Open Source ihris Approach
Better Data, Stronger Health Workforce The Open Source ihris Approach Dykki Settle Team Lead, Health Workforce Informatics, CapacityPlus May 6, 2014 The views expressed in this presentation do not necessarily
More informationThe Ever-increasing Complexity of Biotech Changes - A Pledge for Global Convergence
The Ever-increasing Complexity of Biotech Changes - A Pledge for Global Convergence CMC Strategy Forum, Sorrento, May 7th, 2014 Susanne Ausborn, Pharma Technical Regulatory Policy F. Hoffmann-La Roche,
More informationPage 1/.. USA / Canada - South Africa Schedule No. 4 / 2011-Jan-24
USA / Canada South Africa Schedule No. 4 / 2011Jan24 Page 1/.. USA / Canada South Africa Schedule No. 4 / 2011Jan24 Page 2/.. USA / Canada South Africa Schedule No. 4 / 2011Jan24 Page 3/.. USA / Canada
More informationThe New EU Clinical Trial Regulation Potential Impacts on Sites
The New EU Clinical Trial Regulation Potential Impacts on Sites Angela Papa Associate Director, Clinical Management PPD Pierre-Frédéric Omnes Director, Site Start-Up and Regulatory INC Research Faculty
More informationHealth Products and Food Branch. www.hc-sc.gc.ca
Health Products and Food Branch 1 HEALTH CANADA PART C DIVISION 5 - DRUGS FOR CLINICAL TRIALS INVOLVING HUMAN SUBJECTS Part C - Division 5 2 Part A: Part B: Part C: Part D: Part E: Part G: Part J: Administration
More informationRegulation of clinical trials with medicinal products: Where are we now?
Regulation of clinical trials with medicinal products: Where are we now? Mariantonia Serrano Castro Department of Medicines for Human Use Agencia Española de Medicamentos y Productos Sanitarios (AEMPS)
More informationAIO Life Seminar Abidjan - Côte d Ivoire
AIO Life Seminar Abidjan - Côte d Ivoire Life Insurance Market Survey of Selected African Countries Bertus Thomas Africa Committee of the Actuarial Society of South Africa Agenda SECTION 1 SURVEY OBJECTIVE
More informationThe applicants can submit the eligibility form from 07/01/2016 to 07/02/2016. For additional information, please contact: contact@seed-foundation.
SEED Foundation s 2016 call for proposals for pilot projects in favor of an innovative agricultural development aims at answering this question: how to encourage small structures with limited capacities
More informationScaling up NTD Control: USAID experience. Christy Hanson, PhD, MPH Chief, Infectious Diseases Division
Scaling up NTD Control: USAID experience Christy Hanson, PhD, MPH Chief, Infectious Diseases Division Roadmap to the Neglected Diseases Neglected Diseases HUNDREDS Neglected Tropical Diseases Ascaris Trichuris
More informationClinical Research in Mauritius
BOARD OF INVESTMENT Clinical Research in Mauritius This document provides an informative summary of the procedure to apply for a clinical research protocol in Mauritius. Contents INTRODUCTION... 2 I. APPLICATION
More informationDocument Title: Trust Approval and Research Governance
Document Title: Trust Approval and Research Governance Document Number: SOP034 Staff involved in development: Job titles only Document author/owner: Directorate: Department: For use by: RM&G Manager, R&D
More informationDistance to frontier
Doing Business 2013 Fact Sheet: Sub-Saharan Africa Of the 50 economies making the most improvement in business regulation for domestic firms since 2005, 17 are in Sub-Saharan Africa. From June 2011 to
More informationCorporate Overview Creating Business Advantage
Corporate Overview Creating Business Advantage 14 April 2013 Agenda The power of the group Our achievements Quick facts African regulatory environment Portfolio of offerings Creating value in Africa African
More informationEU Clinical Trials Regulation Regulation EU 536/2014
EU Clinical Trials Regulation Regulation EU 536/2014 María Jesús Zafra Director, QA & Compliance Table of contents 1 2 3 4 Introduction Timelines and main changes Highlights 5 Impact on company processes
More informationClinical Trials and Safety Surveillance of Drugs in Development
Clinical Trials and Safety Surveillance of Drugs in Development Hoda Eid, M.Sc., Ph.D. Manager, ADR Unit Office of Clinical Trials Therapeutic Products Directorate hoda_eid@hc-sc.gc.ca Overview Clinical
More informationQuote Reference. Underwriting Terms. Premium Currency USD. Payment Frequency. Quotation Validity BUPA AFRICA PROPOSAL.
Quote Reference Family Quote 2013 Underwriting Terms BUPA AFRICA PROPOSAL Full Medical Underwriting and/or Continuous PreviousMedical Exclusions Premium Currency USD Payment Frequency One annual payment
More informationEuropean & Developing Countries Clinical Trials Partnership (EDCTP)
European & Developing Countries Clinical Trials Partnership (EDCTP) Overview of EDCTP2 Dr Thomas Nyirenda South-South Networking and Capacity Development Manager 1 Background & Mission Background Established
More informationEBOLA SITUATION REPORT
EBOLA SITUATION REPORT 16 DECEMBER 2015 SUMMARY No confirmed cases of Ebola virus disease (EVD) were reported in the week to 13 December. All contacts associated with the cluster of 3 confirmed cases of
More informationCONTRACT SPECIFICATION
Public document to be completed by the Contracting Authority SERVICE CONTRACT NOTICE Support to the Regional Authorising Officer (ECOWAS Commission) in the implementation of European Development Fund projects
More informationFormal FDA Meeting Request: Guidance and Template
Formal FDA Meeting Request: Guidance and Template ICTR Navigators July 23, 2011 Version 2.0 Page 1 of 20 1.0 Table of Contents Section Page 1.0 Table of Contents 2 2.0 Abbreviations 2 3.0 FDA Regulations
More informationTrial Delivery SOP 05 Trial Archiving
Gloucestershire Research and Development Consortium Standard Operating Procedure R&D SOP TD 05Trial Archiving Trial Delivery SOP 05 Trial Archiving IT IS THE RESPONSIBILITY OF ALL USERS OF THIS SOP TO
More informationClinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity
Clinical Trial Oversight: Ensuring GCP Compliance, Patient Safety and Data Integrity Michelle Quaye Regulatory Manager, Advanced Therapy Trials University College London Overview The Principles of Good
More informationEligibility List 2015
The Global Fund adopted an allocation-based approach for funding programs against HIV/AIDS, TB and malaria in 2013. The Global Fund policy states that countries can receive allocation only if their components
More informationWorldwide Training Funds Project FY 82 Final Report. S&T/POP/IT Assessment of Courses
Worldwide Training Funds Project FY 8 Final Report 6 _+S-/pp SUMMARY The Worldwide Training Funds Project (WW'TF) was established in 97 to train key population/family planning personnel from LDCs which
More informationPROCEDURE FOR PREPARING GCP INSPECTIONS REQUESTED BY THE EMEA. GCP Inspectors Working Group
European Medicines Agency Inspections London, 20 September 2007 EMEA/INS/GCP/197228/2005 Procedure no.: INS/GCP/2 PROCEDURE FOR PREPARING GCP INSPECTIONS REQUESTED BY THE EMEA GCP Inspectors Working Group
More informationExtemporaneously Prepared Early Phase Clinical Trial Materials
Extemporaneously Prepared Early Phase Clinical Trial Materials Richard Hoffman, MS, RAC Eli Lilly & Co. Regulatory Advisor International Consortium for Innovation & Quality in Pharmaceutical Development
More informationIndustry Experience in Clinical Trials Management. Catherine Lee Area Head Clinical Operations Asia Pfizer Inc 20 May 2011 Brussels
Industry Experience in Clinical Trials Management Catherine Lee Area Head Clinical Operations Asia Pfizer Inc 20 May 2011 Brussels Stakeholders in clinical research Critical activities to ensure patient
More informationSocial security quantitative training for Africa (Quatrain) - RBSA Final Evaluation
Social security quantitative training for Africa (Quatrain) - RBSA Final Evaluation Quick Facts Countries: Burundi, Cameroon, Guinea, Lesotho, Madagascar, Mozambique, Namibia, Nigeria, Rwanda, Senegal,
More informationThis note provides additional information to understand the Debt Relief statistics reported in the GPEX Tables.
Technical Note 3 Debt Relief This note provides additional information to understand the Debt Relief statistics reported in the GPEX Tables. Introduction 1. Debt is a major development issue. There is
More informationAnnex A. Levels 1 5 of the Clinical Research Coordinator Track in the Clinical Research WSQ Framework
Annex A Levels 1 5 of the Clinical Research Coordinator Track in the Clinical Research WSQ Framework WSQ Higher Certificate in Clinical Research (Clinical Research Coordinators) Apply Drug Development
More information4 FAH-2 H-821 CASHIER BANK ACCOUNTS
4 FAH-2 H-820 CASHIER BANK ACCOUNTS (CT:DOH-34; 07-23-2013) (Office of Origin: CGFS/FPRA/FP) 4 FAH-2 H-821 CASHIER BANK ACCOUNTS (CT:DOH-34; 07-23-2013) a. Under certain circumstances, a cashier may be
More informationUNAIDS 2013 AIDS by the numbers
UNAIDS 2013 AIDS by the numbers 33 % decrease in new HIV infections since 2001 29 % decrease in AIDS-related deaths (adults and children) since 2005 52 % decrease in new HIV infections in children since
More informationRegulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective
Regulatory Pathways for Licensure and Use of Ebola Virus Vaccines During the Current Outbreak FDA Perspective Office of Vaccines Research and Review Center for Biologics Evaluation and Research U.S. Food
More informationAFRICAN UNION ROADMAP: PROGRESS IN THE FIRST YEAR
AFRICAN UNION ROADMAP: PROGRESS IN THE FIRST YEAR Update on progress to implement the African Union Roadmap on Shared Responsibility and Global Solidarity for AIDS, TB and Malaria Response in Africa (2012
More informationThe Concept of Quality in Clinical Research. Dorota Śwituła Senior Clinical Quality Assurance Advisor
The Concept of Quality in Clinical Research Dorota Śwituła Senior Clinical Quality Assurance Advisor 1 Agenda What is quality? How we define quality in clinical research? The standard components of a Quality
More informationThe Trade Finance Bank for Africa
The Role of Afreximbank and of IFG Africa Chapter in the development of Factoring in Africa By Chairperson, Africa Chapter. B.O. Oramah and Executive Vice-President (AFREXIMBANK) Presentation at the First
More informationWHO Global Health Expenditure Atlas
WHO Global Health Expenditure Atlas September 214 WHO Library Cataloguing-in-Publication Data WHO global health expenditure atlas. 1.Health expenditures statistics and numerical data. 2.Health systems
More informationA Clinical Research Coordinator for an International Study THE GYMNAST
A Clinical Research Coordinator for an International Study THE GYMNAST Anita Ng Research Coordinator The Scarborough Hospital May 12, 2007. 1. What is Research? 2. Characteristics of a Clinical Research
More informationUK Implementation of the EU Clinical Trial Directive 2001/20/EC:
UK Implementation of the EU Clinical Trial Directive 2001/20/EC: GCP Aspects. Dr. Colin Wilsher, FRQA. BARQA GCP Committee Chairman; & Pfizer Worldwide Development Quality Assurance. GIQAR, Roma, October
More informationGlobal Fuel Economy Initiative Africa Auto Club Event Discussion and Background Paper Venue TBA. Draft not for circulation
Global Fuel Economy Initiative Africa Auto Club Event Discussion and Background Paper Venue TBA Draft not for circulation Launched on March 4, 2009 by the United Nations Environment Programme (UNEP), the
More informationINDEPTH/ WITS Scientific and Leadership Development Initiative
INDEPTH/ WITS Scientific and Leadership Development Initiative K S Tint and K Klipstein-Grobusch School of Public Health University of the Witwatersrand Johannesburg Background INDEPTH identified the need:
More informationThe Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner. May 2010
The Clinical Trials Directive in the EU: Present and Future Elisabethann Wright, Partner Maurits Lugard, Partner May 2010 Background (1) The Clinical Trials Directive 2001/20/EC The intention of this Directive
More informationBADEA EXPORT FINANCING SCHEME (BEFS) GUIDELINES
BADEA EXPORT FINANCING SCHEME (BEFS) GUIDELINES 1 P.O. Box 5925 Jeddah 21432 Kingdom of Saudi Arabia Telephone: 636 1400 Telex: 601137-601407 ISDB SJ Facsimile: 636 6871 Jeddah (IDB) Facsimile: 637 1064
More informationTheme II: CREATING, PROMOTING AND SUSTAINING AN INNOVATIVE ENVIRONMENT: Funding, Tax and Other Incentives for Promoting Innovation
Theme II: CREATING, PROMOTING AND SUSTAINING AN INNOVATIVE ENVIRONMENT: Funding, Tax and Other Incentives for Promoting Innovation African Conference on the Strategic Importance of Intellectual Property
More informationTechnical Support Facility for West and Central Africa. Regional Training on Strategic and Operational Planning in HIV and AIDS.
Technical Support Facility for West and Central Africa Regional Training on Strategic and Operational Planning in HIV and AIDS 6-9 April 2010 Accra, Ghana Background UNAIDS Technical Support Facility for
More informationHollie Goddard Sr. IRB Coordinator McKesson Specialty Health
Hollie Goddard Sr. IRB Coordinator McKesson Specialty Health We are responsible for acquiring, analyzing, and protecting medical information vital to providing quality patient care HIM professionals ensure
More informationKIGALI DECLARATION ON THE DEVELOPMENT OF AN EQUITABLE INFORMATION SOCIETY IN AFRICA
KIGALI DECLARATION ON THE DEVELOPMENT OF AN EQUITABLE INFORMATION SOCIETY IN AFRICA We, the Representatives of the African Parliaments to the Kigali International Conference Recalling the commitment of
More informationPensions Core Course Mark Dorfman The World Bank. March 7, 2014
PENSION PATTERNS & REFORM CHALLENGES IN SUB-SAHARAN AFRICA Pensions Core Course Mark Dorfman The World Bank Slide 1 Organization 1. Design summary 2. Challenges 3. Design reform principles 4. A process
More informationA clinical research organization
A clinical research organization About Us State of art facility. All clinical trials carried out in accordance with ICH GCP guidelines. Quality services within stipulated time period. Team of experienced
More informationDoing Business 2015 Fact Sheet: Sub-Saharan Africa
Doing Business 2015 Fact Sheet: Sub-Saharan Africa Thirty-five of 47 economies in Sub-Saharan Africa implemented at least one regulatory reform making it easier to do business in the year from June 1,
More informationAgricultural Development Young Professionals Internship Program Call for Applications
Agricultural Development Young Professionals Internship Program Call for Applications Opening Date: July 31, 2015 Closing Date: September 1, 2015 Africa Lead II the Feed the Future: Building Capacity for
More informationThe West Africa Quality System
The West Africa System REACHING EXCELLENCE THROUGH QUALITY Support to the Implementation of the ECOWAS Policy Context Following a successful fi rst phase from 2001 to 2005, the second phase of the West
More informationEnabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV
Enabling Discovery, Development, and translation of treatments for Cognitive Dysfunctions in Depression: A Workshop Session IV Maria Isaac, MASc, MD, PhD, MFPM, Psychiatrist Senior Scientific Officer Institute
More informationUS Perspective on the Regulatory Assessment of Benefit-Risk of Vaccines
US Perspective on the Regulatory Assessment of Benefit-Risk of Vaccines Norman W. Baylor Biologics Consulting Group, Inc. 23-25 June 2014 Foundation Merieux Conference Center OUTLINE OF PRESENTATION Introduction
More informationEssential Documents for Clinical Trial Research. Centre for Health Evaluation and Outcome Sciences Manager, Clinical Research Development Office
Essential Documents for Clinical Trial Research Erin Cherban, MSc., CCRP Centre for Health Evaluation and Outcome Sciences Manager, Clinical Research Development Office Document Examples See the following
More information